VvAA

Viva Biotech provides comprehensive structure-based drug discovery services from early-stage research through commercial manufacturing. Their offerings include protein expression/purification/structure determination, hit screening, medicinal chemistry, antibody discovery/engineering/humanization/production/bioassay services. They have recently launched an AI-driven drug discovery platform and expanded globally with new branches in Boston. The company supports both small molecules and biologics including advanced modalities like PROTACs and XDCs. They do not develop their own clinical pipeline but enable clients' pipelines.